# RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir

> **NCT00219310** · PHASE4 · COMPLETED · sponsor: **Novartis**

## Conditions studied

- Recurrent Genital Herpes (RGH)

## Interventions

- **DRUG:** Famciclovir

## Key facts

- **NCT ID:** NCT00219310
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2005-06
- **Final completion:** 2005-06
- **Target enrollment:** — (—)
- **Last updated:** 2012-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00219310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00219310, "RELIEF: Randomized Episodic Versus Long-Term Suppression Experience With Famciclovir". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00219310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*